<DOC>
	<DOC>NCT01439971</DOC>
	<brief_summary>This study hypothesizes that the study drug, PF-05280602 (at the selected doses) will be safe to administer to subjects with severe Hemophilia A or B with or without inhibitors and will demonstrate evidence of hemostatic activity. This is supported by the preclinical findings in hemophilic animal models.</brief_summary>
	<brief_title>Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<criteria>Male subjects 18 to &lt;65 years old with severe hemophilia A or B with or without inhibitors to FVIII or FIX. Subjects is willing and able to comply with the mandatory washout periods prior to screening and prior to dosing and through 48 hours post dosing. At screening this includes a washout of FIX for 96 hours and FVIII for 72 houts. At dosing this includes a washout of FIX for 96 hours and FVIII and other hemostatic agents for 72 hours through 48 hours post dosing. Subjects must agree and commit to using a a highly effective method of birth control from the time of screening through four weeks after study drug administration. Presence of a bleeding disorder in addition to hemophilia A or B. Regular, concomitant therapy with immunomodulating drugs (eg, intravenous immunoglobulin, and routine systemic corticosteroids). History of coronary artery disease, thrombolic disease or diagnosis of prothrombic disorder.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Safety</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>Pharmacodynamic</keyword>
</DOC>